Home  /   Products  /   Eye and ear  /   Timolol, travoprost (Travalza Duo) eye drops 5 mg/ml + 0.04 mg/ml – [2.5 ml vial]
Timolol, travoprost (Travalza Duo) eye drops 5 mg/ml + 0.04 mg/ml - [2.5 ml vial]

Timolol, travoprost (Travalza Duo) eye drops 5 mg/ml + 0.04 mg/ml – [2.5 ml vial]

$36.43

combined antiglaucoma drug (synthetic prostaglandin f2-alpha analogue + beta-adrenoblocker)

SKU: 62989 Category:

Description

Travalza Duo Pharmacodynamics
TRAVALZA® DUO contains two active substances: travoprost and timolol.
Both components reduce intraocular pressure. Due to the complementary mechanisms of action, decrease of intraocular pressure under the influence of combination is more significant than action of each component separately.
Timolol
Timolol is a non-selective blocker of beta-adrenoreceptors without sympathomimetic activity, it has no direct depressant effect on the myocardium, and has no membrane stabilizing activity. When applied topically it reduces intraocular pressure by reducing aqueous humor formation and slightly increasing its outflow.
Travoprost
Travoprost is an analogue of prostaglandin F2-alpha, is a highly selective agonist of prostaglandin FP-receptors and decreases intraocular pressure by increasing outflow of aqueous humor. The main mechanism of action of the drug is associated with an increase in uveoscleral outflow. It does not significantly affect the production of aqueous humor.
Intraocular pressure decreases approximately 2 hours after application, the maximum effect is achieved after 12 hours. Significant decrease in intraocular pressure may persist for 24 hours after a single use of the drug.

 

Indications
The reduction of elevated intraocular pressure in open-angle glaucoma and intraocular hypertension in patients resistant to beta-adrenoblocker or prostaglandin analogues monotherapy.

 

Contraindications
– Hypersensitivity to the active substances or to any of the excipients.
– Hypersensitivity to other beta-adrenoblockers.
– Reactive airways disease, including bronchial asthma (including history) and severe chronic obstructive pulmonary disease (COPD).
– Sinus bradycardia, sinus node weakness syndrome, including sinoatrial block, grade II or III atrioventricular block without a pacemaker.
– Decompensated chronic heart failure.
– Cardiogenic shock.
– Allergic rhinitis of a severe course.
– Corneal dystrophy.
– Pregnancy.
– Breast-feeding period.
– Childhood under 18 years of age (safety and effectiveness has not been established).

 

Dosage and administration method

 

  • Topically.
  • The drug is applied by 1 drop in the conjunctival sac of the eye once a day, in the evening or in the morning at the same time.
  • To reduce the risk of systemic side effects it is recommended to press on the nasolacrimal duct after instillation by applying pressure to the duct projection at the inner corner of the eye.
  • If a dose of the drug was missed, treatment should be continued with the next dose. Daily dose of the drug should not exceed 1 drop in the conjunctival sac of the eye once a day.
  • Timolol+Travoprost may be used in combination with other local ophthalmic drugs to reduce intraocular pressure. In this case the interval between their application should be at least 5 minutes.
  • Do not touch the tip of the dropper bottle to any surface in order to avoid contamination of the dropper bottle and its contents.
  • The dropper bottle should be closed after each use.

Related products